CPSE:NOVO BPharmaceuticals
Is Novo Nordisk (CPSE:NOVO B) Undervalued Following CEO Obesity Market Comments?
Novo Nordisk (CPSE:NOVO B) is back in focus after its CEO argued that investors may be undervaluing the long term potential of obesity treatments, along with fresh signals on the company’s shareholder return plans.
See our latest analysis for Novo Nordisk.
Novo Nordisk’s recent CEO comments and ongoing buyback and dividend plans come after a mixed run, with the share price up 2.76% over 90 days but down 10.17% over 30 days and the 1 year total shareholder return declining 10.80%, while the 3...